Novo Nordisk seeks EU nod for higher dose of its weight-loss drug Wegovy
HQ Team July 8, 2025: Novo Nordisk A/S has sought approval from the European Medicines Agency for a higher dose of its weight-loss.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team July 8, 2025: Novo Nordisk A/S has sought approval from the European Medicines Agency for a higher dose of its weight-loss.
HQ Team June 28, 2025: World leaders have pledged $9 billion to support Gavi, the Vaccine Alliance, for the next five years after.
HQ Team June 22, 2025: Madrigal Pharmaceuticals EU Limited’s therapy to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) got a conditional marketing.
HQ Team May 20, 2025: The UN, facing a funding crisis following global budget cuts, is at risk of eroding its credibility and.
HQ Team April 16, 2025: Eisai Co., Ltd. and Biogen Inc.’s drug to treat Alzheimer’s disease got marketing authorisation in the European Union,.
HQ Team April 15, 2025: Bristol Myers Squibb’s end-phase trial to test a drug for treating a heart condition, where the muscle of.
HQ Team April 4, 2025: AstraZeneca’s combination drug for the treatment of adults with resectable non-small cell lung cancer has got approval from.
AstraZeneca’s drug for treating limited-stage small cell lung cancer got a recommendation for approval from an EU regulator panel, according to the British-Swedish.
Vertex Pharmaceuticals Inc.’s Alyftrek drug got clearance from the Food and Drug Administration to expand its treatment for cystic fibrosis in people six.
The EU faces a new set of healthcare challenges potentially more potent than the Covid-19 pandemic, and some states are “miles away” from.